Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research ("AACR") Annual Meeting

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul><li><em>NXP800 demonstrated robust antitumor activity in two patient-derived xenograft ("PDX") models of cholangiocarcinoma</em></li><li><em>Research conducted by investigators from the Mayo Clinic in Rochester, MN</em></li></ul> <p align="justify">Fort Lee, NJ, April 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the...